Silence Therapeutics plc (SLN) is a biotechnology company that focuses on the development of RNA interference (RNAi) therapeutics. The company utilizes various technical indicators to analyze the stock's performance and assist in making informed investment decisions. These indicators provide valuable insights into the stock's price momentum, trend strength, and volatility.

One of the key technical indicators used for Silence Therapeutics plc (SLN) is the Relative Strength Index (RSI). RSI measures the magnitude and speed of price movements and helps identify overbought or oversold conditions. By analyzing SLN's RSI, investors can ascertain whether the stock is currently overbought or oversold and make appropriate trading decisions.

Silence Therapeutics plc (SLN) Technical Analysis

Discover technical indicators such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR for Silence Therapeutics plc (SLN) stock. Gain insights into the technical analysis rating of SLN stock.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics plc

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	80.10	Sell	44.3%
auto_graphMACD	116.18	Neutral	275.7%
auto_graphCCI	150.41	Sell	150.3%
auto_graphADX	56.36	Neutral	-
auto_graphATR	71.61	Buy	-
auto_graphWILLR	-2.73	Sell	176.3%
auto_graphROC	157.28	Neutral	402.7%
auto_graphSTOCHRSI	50.58	Neutral	193.0%

Buy	1	-87.50%
Hold	4	-50.00%
Sell	3	-62.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Silence Therapeutics plc (SLN) Technical Analysis

Keep an eye on Silence Therapeutics plc

Frequently Asked Questions

What are the technical signals for Silence Therapeutics plc (SLN) stock based on the last 30 days?

Take Your Investments to a Whole New Level